Raymond James Financial
SLN

Raymond James Financial’s Silence Therapeutics SLN Stock Holding History

Raymond James Financial’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$165K Sell
15,000
-10,000
-40% -$70.4K ﹤0.01% 5085
2026
Q1 		$132K Hold
25,000
– – ﹤0.01% 4981
2025
Q4 		$152K Buy
+25,000
New +$160K ﹤0.01% 4849

Other funds holding SLN

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Raymond James Financial's SLN Position: Q2 2026 in Review

Raymond James Financial reduced its Silence Therapeutics (SLN) stake by 40% in Q2 2026, selling an estimated $70.4K and leaving 15,000 shares worth $165K. The position accounts for ﹤0.01% of the portfolio, ranked #5085.

Raymond James Financial first reported a position in SLN in Q4 2025 and has held it in 3 quarters since. 72 funds tracked by Wall St. Rank hold SLN as of Q2 2026.

  • Raymond James Financial held 15,000 shares of Silence Therapeutics worth $165K as of Q2 2026.
  • Raymond James Financial sold 10,000 Silence Therapeutics shares in Q2 2026, an estimated $70.4K.
  • Silence Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #5085 holding.
  • Raymond James Financial first reported a position in Silence Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 72 funds tracked by Wall St. Rank held Silence Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.